Autologous CD33/CD123 dual-target CAR-T module not checked
FollowEvery change as it happens, and a Monday email
Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Biological: Autologous CD33/CD123 dual-target CAR-T module (simultaneous or planned sequential paired infusion, module-specific) after lymphodepletion.”In the company’s words, NCT07523555 on ClinicalTrials.gov
- Tested for
- Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm, BPDCN; Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
- Main trialPhase 1/2
- “Phase 1/2 umbrella study evaluates biomarker-selected dual-target CAR-T cell modules for adults with relapsed or refractory hematologic malignancies. After central antigen co-expression screening, participants are assigned to the most appropriate active dual-target module: CD19/CD22, CD19/CD20, BCMA/CD19, BCMA/CD38, BCMA/GPRC5D, CD33/CD123, CD33/CLL1, or CD5/CD7. Phase 1 determines safety, dose-limiting toxicities, and the recommended phase 2 dose for each module; phase 2 estimates preliminary antitumor activity, including overall response rate and MRD-negative response. Lymphodepletion with…”In the company’s words, NCT07523555 on ClinicalTrials.gov
Other drugs for T-lymphoblastic Lymphoma
- WU-CART-007Allotera Therapeutics · Phase 2
- Autologous BCMA/CD19 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
- Autologous BCMA/CD38 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
- Autologous BCMA/GPRC5D dual-target CAR-TBeijing Biotech · Phase 1/2
- Autologous CD19/CD20 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
- Autologous CD19/CD22 dual-target CAR-T moduleBeijing Biotech · Phase 1/2
Coming up1
- 14 Mar 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 14 Mar 2027 | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026